Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Show full item record



Permalink

http://hdl.handle.net/10138/237301

Citation

Koskela , H L M , El Missiry , M , Ruusila , A , Koskenvesa , P , Bruemmendorf , T H , Gjertsen , B T , Janssen , J , Lotfi , K , Markevarn , B , Olsson-Stromberg , U , Stenke , L , Stentoft , J , Richter , J , Hjorth-Hansen , H , Kreutzman , A & Mustjoki , S 2017 , ' Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia ' , Journal of Cancer Research and Clinical Oncology , vol. 143 , no. 8 , pp. 1543-1554 . https://doi.org/10.1007/s00432-017-2378-6

Title: Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia
Author: Koskela, Hanna L. M.; El Missiry, Mohamed; Ruusila, Anniina; Koskenvesa, Perttu; Bruemmendorf, Tim H.; Gjertsen, Bjorn T.; Janssen, Jeroen; Lotfi, Kourosh; Markevarn, Berit; Olsson-Stromberg, Ulla; Stenke, Leif; Stentoft, Jesper; Richter, Johan; Hjorth-Hansen, Henrik; Kreutzman, Anna; Mustjoki, Satu
Contributor organization: Clinicum
Hematologian yksikkö
Department of Oncology
University of Helsinki
Department of Medicine
Medicum
Department of Clinical Chemistry and Hematology
HUS Comprehensive Cancer Center
HUSLAB
HUS Internal Medicine and Rehabilitation
Date: 2017-08
Language: eng
Number of pages: 12
Belongs to series: Journal of Cancer Research and Clinical Oncology
ISSN: 0171-5216
DOI: https://doi.org/10.1007/s00432-017-2378-6
URI: http://hdl.handle.net/10138/237301
Abstract: Purpose Tyrosine kinase inhibitors (TKIs) have well-characterized immunomodulatory effects on T and NK cells, but the effects on the humoral immunity are less well known. In this project, we studied TKI-induced changes in B cell-mediated immunity. Methods We collected peripheral blood (PB) and bone marrow (BM) samples from chronic myeloid leukemia (CML) patients before and during first-line imatinib (n = 20), dasatinib (n = 16), nilotinib (n = 8), and bosutinib (n = 12) treatment. Plasma immunoglobulin levels were measured, and different B cell populations in PB and BM were analyzed with flow cytometry. Results Imatinib treatment decreased plasma IgA and IgG levels, while dasatinib reduced IgM levels. At diagnosis, the proportion of patients with IgA, IgG, and IgM levels below the lower limit of normal (LLN) was 0, 11, and 6% of all CML patients, respectively, whereas at 12 months timepoint the proportions were 6% (p = 0.13), 31% (p = 0.042) and 28% (p = 0.0078). Lower initial Ig levels predisposed to the development of hypogammaglobulinemia during TKI therapy. Decreased Ig levels in imatinibtreated patients were associated with higher percentages of immature BM B cells. The patients, who had low Ig levels during the TKI therapy, had significantly more frequent minor infections during the follow-up compared with the patients with normal Ig values (33% vs. 3%, p = 0.0016). No severe infections were reported, except recurrent upper respiratory tract infections in one imatinib-treated patient, who developed severe hypogammaglobulinemia. Conclusions TKI treatment decreases plasma Ig levels, which should be measured in patients with recurrent infections.
Subject: CML
Tyrosine kinase inhibitor
B cell
Immunoglobulin
PATIENTS RECEIVING IMATINIB
CHRONIC-PHASE
PHILADELPHIA-CHROMOSOME
BONE-MARROW
FOLLOW-UP
DASATINIB
NILOTINIB
ANTIGEN
HYPOGAMMAGLOBULINEMIA
COMBINATION
3122 Cancers
Peer reviewed: Yes
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
10.1007_s00432_017_2378_6.pdf 812.1Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record